Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR2A | P28223 | 5/20 | 0.38 |
| ▸ | HTR2C | P28335 | 5/20 | 0.38 |
| ▸ | HTR2B | P41595 | 5/20 | 0.38 |
| ▸ | HRH3 | Q9Y5N1 | 4/20 | 0.38 |
| ▸ | DPP4 | P27487 | 2/20 | 0.37 |
| ▸ | ACHE | P22303 | 1/20 | 0.36 |
| ▸ | SLC6A2 | P23975 | 2/20 | 0.35 |
| ▸ | SLC6A4 | P31645 | 2/20 | 0.35 |
| ▸ | SLC6A3 | Q01959 | 2/20 | 0.35 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.35 |
| ▸ | DHFR | P00374 | 1/20 | 0.34 |
| ▸ | KDM1A | O60341 | 1/20 | 0.34 |
| ▸ | MAOA | P21397 | 1/20 | 0.34 |
| ▸ | MAOB | P27338 | 1/20 | 0.34 |
| ▸ | RELA | Q04206 | 1/20 | 0.34 |
| ▸ | CACNA1S | Q13698 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4785890 | 0.87 | OPRM1 (0.38) | HTR2AHTR2CHTR2BHRH3DPP4 | |
| SCHEMBL4787414 | 0.82 | DPP4 (0.43) | HTR2AHTR2CHTR2BHRH3DPP4 | |
| SCHEMBL4787375 | 0.82 | HTR2A (0.37) | HTR2AHTR2CHTR2BHRH3DPP4 | |
| SCHEMBL4786927 | 0.82 | DHFR (0.44) | HTR2AHTR2CHTR2BHRH3DPP4 | |
| SCHEMBL4787329 | 0.81 | KDM1A (0.37) | HTR2AHTR2CHTR2BHRH3DPP4 | |
| SCHEMBL4783552 | 0.78 | SLC6A2 (0.41) | HTR2AHTR2CHTR2BHRH3ACHE | |
| SCHEMBL4783420 | 0.78 | BCHE (0.42) | ACHE | |
| SCHEMBL4930959 | 0.76 | HTR2A (0.39) | HTR2AHTR2CHTR2BHRH3DPP4 | |
| SCHEMBL4785505 | 0.76 | HTR2A (0.37) | HTR2AHTR2CHTR2BHRH3DPP4 | |
| SCHEMBL4783845 | 0.75 | HTR2A (0.36) | HTR2AHTR2CHTR2BHRH3SLC6A2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2008089310-A2 | DELTA 5 DESATURASE INHIBITORS FOR THE TREATMENT OF OBESITY | LEXICON PHARMACEUTICALS, INC. (US) | 2008-07-24 | — | — | WO | claimed |
| WO-2008089307-A2 | DELTA 5 DESATURASE INHIBITORS FOR THE TREATMENT OF PAIN, INFLAMMATION AND CANCER | LEXICON PHARMACEUTICALS, INC. (US) | 2008-07-24 | — | — | WO | claimed |
| US-20080200458-A1 | Methods and compositions for the treatment of body composition disorders | LEXICON PHARMACEUTICALS, INC. | 2008-08-21 | — | — | US | disclosed |
| US-20080194557-A1 | Methods and compositions for the treatment of pain, inflammation and cancer | LEXICON PHARMACEUTICALS, INC. | 2008-08-14 | — | — | US | disclosed |
| WO-2008089310-A2 | DELTA 5 DESATURASE INHIBITORS FOR THE TREATMENT OF OBESITY | LEXICON PHARMACEUTICALS, INC. (US) | 2008-07-24 | — | — | WO | disclosed |
| WO-2008089307-A2 | DELTA 5 DESATURASE INHIBITORS FOR THE TREATMENT OF PAIN, INFLAMMATION AND CANCER | LEXICON PHARMACEUTICALS, INC. (US) | 2008-07-24 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080194557-A1 | Methods and compositions for the treatment of pain, inflammation and cancer | TNF, IL6, CXCL8 | HTR2A 1056/4885HTR2C 1422/4885HTR2B 1566/4885 |
| US-20080200458-A1 | Methods and compositions for the treatment of body composition disorders | CPT1B, CPT1A, SHBG | HTR2A 1983/4885HTR2C 2027/4885HTR2B 2293/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.